AllDocs -> cancers

A Snapshot of the Ovarian Cancer National Alliance WHO: The Ovarian Cancer National Alliance is the nation’s voice for ovarian cancer issues. The Alliance leads the national movement to conquer ovarian cancer by uniting local, state and national organizations reaching 800,000 people. As a 501(c)(3) nonprofit organization, the Alliance is funded through a mix of corporate and foundation gifts as well as individual contributions. WHY: Ovarian cancer knows no boundaries or borders, prematurely killing women of every age, ethnicity and socioeconomic status. It is the deadliest of all the cancers of the reproductive system and a leading cause of cancer death among women. Its symptoms are subtle, difficult to diagnose and often misdiagnosed. Because there is no reliable screening test , fewer than one in five women are diagnosed in the early stages. However, with early ...

Genetic testing for susceptibility to breast and ovarian cancer : Evaluating the impact of a direct-to-consumer marketing campaign on physicians’ knowledge and practices Melanie F. Myers, PhD, MS 1 , Man-Huei Chang, MPH 1 , Cynthia Jorgensen, PhD 2 , William Whitworth, MPH 1 , Sidibe Kassim, MD 3 , James A. Litch, MD, DTMH 3 , Lori Armstrong, PhD 4 , Barbara Bernhardt, MS 5 , W. Andrew Faucett, MS 6 , Debra Irwin, PhD, MSPH 7 , Judy Mouchawar, MD, MSPH 8 , and Linda A. Bradley, PhD 1 Purpose: To assess the impact of direct-to-consumer marketing of genetic testing for risk of breast and ovarian cancer by a biotechnology company on: 1) physicians’ knowledge; 2) reasons ...

100 Title 3—The President Proc. 7919 founding of the country and was furthered by the 1848 women’s rights con- vention in Seneca Falls, New York. By celebrating Women’s Equality Day, we commemorate the adoption of this amendment and honor the visionary women who fought tirelessly for women’s suffrage. Led by women such as Elizabeth Cady Stanton, Susan B. Anthony, and Lucretia Mott, the suffragists stood up against injustice and persevered until, as Susan B. Anthony wrote, the handful who first took a stand for suffrage grew into an army. The efforts of these pioneers helped secure for American women the right to vote. Since the adoption of the 19th Amendment, women have continued to make great contributions to our Nation. Women today are leaders in medi- cine, law, journalism, business, government, and other professions. They are doctors and mothers, teachers and lawyers, homemakers ...

78 Title 3—The President Proc. 7810 Proclamation 7810 of September 10, 2004 National Ovarian Cancer Awareness Month, 2004 By the President of the United States of America A Proclamation Ovarian cancer affects thousands of Americans each year. During this time of tremendous medical breakthroughs, we are seeing progress in the effort to overcome this disease, but our work is not finished. National Ovarian Cancer Awareness Month provides an opportunity for our citizens to learn more about early detection and treatment for this deadly cancer . Although new cases of ovarian cancer in the United States have been de- creasing for more than a decade, the American Cancer Society estimates that about 25,000 women will be diagnosed this year and over 16,000 will die from the disease. Family and personal history can affect the likelihood of developing ...

2004 • 2005 Directory of Genetics Support Groups, Services and Information 307 Produced by the Centre for Genetics Education. Fax: (02) 9906 7529 Email: genetics@med.usyd.edu.au Internet: http://www.genetics.com.au BREAST AND OVARIAN CANCER – GENETIC ASPECTS 45 BREAST AND OVARIAN CANCER • Breast cancer is the commonest form of cancer occurring in women in Australia. It affects about 1 in 12 women in their lifetime. • Cancer of the ovaries affects only about 1 in 100 women before the age of 75. However, it is the leading cause of death from gynaecological cancer . Breast cancer also occurs in men, but it is rare. CAUSES OF BREAST/ OVARIAN CANCER The causes of breast and ovarian cancer are complex and involve interactions between genetic and environmental factors. (a) Genetic factors Cancer is a disease of the body’s cells. ...

OVARIAN CANCER Ovarian cancer causes more deaths than any other cancer of the female reproductive system. Known Risk Factors • Family history of ovarian , breast or colon cancer • Personal history of breast, endometrial or colon cancer • Postmenopausal women • Born with an alteration in the BRAC1 or BRAC2 gene • Not bearing children • Infertility and/or late menopause Possible Risk Factors • Use of talc based genital powders • Use of fertility drugs • Hormone replacement therapy (HRT) Factors That May Lower Risk • Use of oral contraceptives • Breastfeeding • Tubal ligation or hysterectomy • Low fat diet • Having the ovaries removed Symptoms • Bloating, ...

1 APPLICATION OF A POLYGENIC MODEL OF BREAST AND OVARIAN CANCER TO CRITICAL ILLNESS INSURANCE By Angus Macdonald and Kenneth McIvor abstract Mutations in the BRCA1 and BRCA2 genes confer very high risk of breast cancer (BC) but only account for about 25% of the observed familial clustering of BC. Antoniou et al. (2002) proposed a model that included the BRCA1 and BRCA2 genes, and a polygenic component that acted multiplicatively on the rate of onset of BC. We use this model to find premium rates for critical illness insurance: (a) given knowledge of an applicant’s polygenotype; and (b) given knowledge of a family history of BC or ovarian cancer . We find that the polygenic component causes large variation in premium rates even among non-mutation carriers, therefore affecting the whole population. In some cases the polygenic contribution is protective enough to reduce or remove the additional risk ...

Page 1 of 9 Coverage Position Number: 0321 C IGNA H EALTH C ARE C OVERAGE P OSITION Subject Stem-Cell Transplant for Ovarian Cancer Revised Date ..4/15/2006 Original Effective Date .4/15/2005 Coverage Position Number . 0321 Table of Contents Coverage Position..1 General Background .1 Coding/Billing Information..7 References.8 Hyperlink to Related Coverage Positions INSTRUCTIONS FOR USE Coverage Positions are intended to supplement certain standard CIGNA HealthCare benefit plans. Please note, the terms of a participant’s particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard ...

1 DNA Biomarkers Possessing Methylation-Predictive Sequence Patterns in Ovarian Cancer Susan H. Wei 1* , Curtis Balch 2* , Henry H. Paik 2* , Yoo-Sung Kim 2,3 , Rae Lynn Baldwin 4 , Sandya Liyanarachchi 1 , Lang Li 5 , Zailong Wang 6 , Joseph C. Wan 1 , Ramana V. Davuluri 1 , Beth Y. Karlan 4 , Gillian Gifford 7 Robert Brown 7 , Sun Kim 8 , Tim H.-M. Huang 1 , Kenneth P. Nephew 2,9,# 1 Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA 2 Medical ...

More than a decade ago, scientists discovered that defects in two specific genes (BRCA1 and BRCA2) were linked to breast cancer . The finding confirmed that breast cancer risk could be passed from one generation to the next through those genes. But many women are not aware of another danger hiding in the shadows of the breast cancer genes: ovarian cancer . Unlike breast cancer or cervical cancer , ovarian cancer has no reliable screening test, and symptoms are vague or nonexistent. For these reasons, ovarian cancer typically is diagnosed at an advanced stage, when the disease is difficult to cure. But there are clues that could alert a woman to her potential risk. “Some families appear to be especially susceptible to cancer ,” says Tara Namey, certified genetic counselor in Lehigh Valley Hospital and Health Network’s cancer risk assessment program. “If you have a strong family his- tory of ...

Page 2 Ovarian cancer in England 1996 to 2004. A geographical profile of mortality. Authors: Michael Goldacre, David Yeates, Leicester Gill, Myfanwy Griffith, Henry McGuinness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South East England Public Health Observatory, 2005 This document provides a geographical profile of mortality from ovarian cancer in England. The geographical areas covered are the standard local authority areas of England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the Public Health Observatories by the Office for National Statistics. This analysis includes mortality data about females of all ages. The map, chart and table show standardised mortality ratios (SMRs). The data in the map are shown as quintiles of local authorities, ...

home > training > resources and tools > perspectives > breast cancer > breast cancer fact sheet Fact Sheet on Genetic Testing for Breast and Ovarian Cancer Susceptibility Introduction Genetic testing for hereditary susceptibility for breast and ovarian cancer is the first genetic test to be marketed directly to consumers. Public health agencies may be called upon to answer questions about this testing from the general public and healthcare providers in their communities. This fact sheet contains information about the genetic test for hereditary susceptibility for breast and ovarian cancer , the clinical context in which it is currently used, and some of the potential ethical and social issues. The burden of breast and ovarian cancer in the United States One in eight (12%) of U.S. women aged 90 years or younger will develop breast cancer ...

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers Kelly A. Metcalfe a,b, * , Henry T. Lynch c , Parviz Ghadirian d , Nadine Tung e , Ivo A. Olivotto f , William D. Foulkes g , Ellen Warner h , Olufunmilayo Olopade i , Andrea Eisen h , Barbara Weber j , Jane McLennan k , Ping Sun b , Steven A. Narod b a Faculty of Nursing, University of Toronto, Toronto, ON, Canada b The Centre for Research in Women’s Health, Sunnybrook and Women’s College Health Sciences Centre, Toronto, ON, Canada c Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE 68178, USA d Epidemiology Research ...

SIGNIFICANT PROPORTION OF BREAST AND/OR OVARIAN CANCER FAMILIES OF FRENCH CANADIAN DESCENT HARBOR 1 OF 5 BRCA1 AND BRCA2 MUTATIONS Kathleen K. O ROS 1 , Parviz G HADIRIAN 2 , Celia M.T G REENWOOD 3 , Chantal P ERRET 4 , Zhen S HEN 5 , Yosabeth P AREDES 2 , Suzanna L. A RCAND 5 , Anne-Marie M ES -M ASSON 4,6 , Steven A. N AROD 7 , William D. F OULKES 1,5,8 , Diane P ROVENCHER 4,9 and Patricia N. T ONIN 1,5,8 * 1 Department of Human Genetics, McGill University, Montreal, Canada 2 Unité de Recherché en Epidémiologie, Centre Hospitalier de l’Université de Montréal, Hôpital ...

GCF/SGO Weekly Media Report Week April 1, 2005 1 Page 3 Cervical Cancer ; Most women willing to accept vaccine for self and children NewsRx; April 7, 2005 Results of a survey of 200 women show that most would be willing to receive a cervical cancer vaccine and would allow it to be administered to their children. Page 5 Ovarian Cancer ; Paper reviews origins and molecular pathology of ovarian cancer NewsRx; April 7, 2005 A paper in a recent issue of Modern Pathology reviewed various types of ovarian cancer , their etiology, and molecular pathology. Page 7 Society of Gynecologic Oncologists; Members of Congress announce national gynecologic cancer awareness campaign NewsRx ;April 6, 2005 The Society of Gynecologic Oncologists (SGO) joined representatives Rosa DeLauro, Kay Granger, Darrell Issa and Sander Levin at a press ...

GCF/SGO Weekly Media Report Week Ending April 15, 2005 1 Page 3 Ovarian Cancer ; Researchers evaluating investigational therapy for ovarian cancer NewsRx; April 19, 2005 For the majority of patients with advanced ovarian cancer , the current standard of care and front-line treatments - surgery and chemotherapy - are not enough to control the high recurrence rate. Page 5 Ovarian Cancer ; BRCA1 mutation acts through indirect, biochemical route NewsRx; April 19, 2005 Mutated BRCA1 genes cause ovarian cancer indirectly, by interfering with the biochemical signals one ovarian cell sends to another, researchers have determined. Page 7 Cancer Vaccines; Majority of women accept cervical cancer vaccine for self, children, study shows NewsRx; April 19, 2005 In a study of 200 women, a group of physicians has found ...

Plasma Bikunin As a Favorable Prognostic Factor in Ovarian Cancer Hidenori Matsuzaki, Hiroshi Kobayashi, Tatsuo Yagyu, Kiyoshi Wakahara, Toshiharu Kondo, Noriyuki Kurita, Hideo Sekino, Kiyokazu Inagaki, Mika Suzuki, Naohiro Kanayama, and Toshihiko Terao A B S T R A C T Purpose Bikunin is a multifunctional glycoprotein, which mediates suppression of tumor cell invasion and metastasis. The measurement of bikunin levels in the tissue of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the evaluation of prognosis. The high bikunin expression in ovarian cancer tissue would enable the use of soluble bikunin protein present in the circulation of ovarian cancer patients as a biomarker of disease. Patients and Methods We developed a double-antibody immunoassay for bikunin and detected its ...

Issue date: May 2005 Review date: February 2008 Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review) Quick reference guide Technology Appraisal Guidance 91 This guidance is written in the following context: This guidance represents the view of the Institute, which was arrived at after careful consideration of the available evidence. Health professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. This guidance will replace the following guidance issued by the Institute: • Ovarian cancer – topotecan; ...